Development and Expansion of Patient-Derived Xenografts for Endometrial Cancer.

Asmerom T Sengal, Pamela M Pollock

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 81% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Asmerom T SengalEndometrial Cancer Laboratory, School of Biomedical Sciences, Faculty of Health, The Queensland University of Technology Located at the Translational Research Institute (TRI), Woolloongabba, Brisbane, QLD, Australia.

Pamela M PollockEndometrial Cancer Laboratory, School of Biomedical Sciences, Faculty of Health, The Queensland University of Technology Located at the Translational Research Institute (TRI), Woolloongabba, Brisbane, QLD, Australia. pamela.pollock@qut.edu.au.

Queensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-Derived Xenografts (PDXs) are established by implanting a fragment of a patient tumor into rodents either subcutaneously or orthotopically. PDX models faithfully recapitulate the histologic and molecular profile of the donor patient's cancer and are regarded as authentic preclinical models for drug testing, understanding of tumor biology and biomarker discovery. This Chapter describes the detailed method for establishing robust PDXs for endometrial cancer and provide important notes for users of the protocol to consider during PDXs development.

Indexed as

Endometrial NeoplasmsXenograft Model Antitumor AssaysAnimalsDisease Models, AnimalFemaleHeterograftsHumansMiceDrug discoveryEndometrial cancerIn vivoLaboratory animalsPatient-derived xenograftPDXPreclinical modelProtocol

Identifiers

PMID38676799

DOI10.1038/bjc.2015.190

OpenAlexW4395698798

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.